Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 307

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results

Rustin, Gordon J.S., Galbraith, Susan M., Anderson, Helen, Stratford, Michael, Folkes, Lisa K., Sena, Luiza, Gumbrell, Lindsey, Price, Patricia M.·2003·Journal of Clinical Oncology

Abstract

Purpose: A phase I trial was performed with combretastatin A4 phosphate (CA4P), a novel tubulin-binding agent that has been shown to rapidly reduce blood flow in animal tumors. Patients and Methods: The drug was delivered by a 10-minute weekly infusion for 3 weeks followed by a week gap, with intrapatient dose escalation. Dose escalation was accomplished by doubling until grade 2 toxicity was seen. The starting dose was 5 mg/m 2. Results: Thirty-four patients received 167 infusions. CA4P was rapidly converted to the active combretastatin A4 (CA4), which was further metabolized to the glucuronide. CA4 area under the curve (AUC) increased from 0.169 at 5 mg/m 2 to 3.29 μmol • h/L at 114 mg/m 2. The mean CA4 AUC in eight patients at 68 mg/m 2 was 2.33 μmol • h/L compared with 5.8 μmol • h/L at 25 mg/kg (the lowest effective dose) in the mouse. The only toxicity that possibly was related to the drug dose up to 40 mg/m 2 was tumor pain. Dose-limiting toxicity was reversible ataxia at 114 mg/m 2, vasovagal syncope and motor neuropathy at 88 mg/m 2, and fatal ischemia in previously irradiated bowel at 52 mg/m 2. Other drug-related grade 2 or higher toxicities seen in more than one patient were pain, lymphopenia, fatigue, anemia, diarrhea, hypertension, hypotension, vomiting, visual disturbance, and dyspnea. One patient at 68 mg/m 2 had improvement in liver metastases of adrenocortical carcinoma. Conclusion: CA4P was well tolerated in 14 of 16 patients at 52 or 68 mg/m 2; these are doses at which tumor blood flow reduction has been recorded.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2003.05.185

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 307

Metadata

Authors
Rustin, G. J. S., Galbraith, S. M., Anderson, H., Stratford, M., Folkes, L. K., Sena, L., Gumbrell, L., & Price, P. M.
Venue
Journal of Clinical Oncology
Published
2003-08-01
Volume
21
Issue
15
Pages
2815-2822
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2056944384
Cited by
307
References
18
FWCI
4.83
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results. https://app.cochat.ai/papers/10.1200/jco.2003.05.185
The paper
Rustin, G. J. S., Galbraith, S. M., Anderson, H., Stratford, M., Folkes, L. K., Sena, L., Gumbrell, L., & Price, P. M. (2003). Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2003.05.185

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.